DE69942782D1 - Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung - Google Patents
Zusammensetzungen und Verfahren zur Erhöhung der KnochenmineralisierungInfo
- Publication number
- DE69942782D1 DE69942782D1 DE69942782T DE69942782T DE69942782D1 DE 69942782 D1 DE69942782 D1 DE 69942782D1 DE 69942782 T DE69942782 T DE 69942782T DE 69942782 T DE69942782 T DE 69942782T DE 69942782 D1 DE69942782 D1 DE 69942782D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- methods
- increasing bone
- bone mineralization
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11028398P | 1998-11-27 | 1998-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69942782D1 true DE69942782D1 (de) | 2010-10-28 |
Family
ID=22332193
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69933044.0T Expired - Lifetime DE69933044T3 (de) | 1998-11-27 | 1999-11-24 | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
DE69942782T Expired - Lifetime DE69942782D1 (de) | 1998-11-27 | 1999-11-24 | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69933044.0T Expired - Lifetime DE69933044T3 (de) | 1998-11-27 | 1999-11-24 | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
Country Status (18)
Country | Link |
---|---|
US (12) | US6395511B1 (de) |
EP (3) | EP1721979B1 (de) |
JP (2) | JP4813660B2 (de) |
CN (2) | CN101469329B (de) |
AT (2) | ATE338120T2 (de) |
BR (1) | BRPI9915679B8 (de) |
CA (1) | CA2352532C (de) |
CY (3) | CY1106260T1 (de) |
DE (2) | DE69933044T3 (de) |
DK (3) | DK2261335T3 (de) |
ES (3) | ES2272093T5 (de) |
HK (2) | HK1044171B (de) |
IL (3) | IL143266A0 (de) |
MX (2) | MXPA01005275A (de) |
NZ (3) | NZ512122A (de) |
PT (3) | PT1721979E (de) |
WO (1) | WO2000032773A1 (de) |
ZA (1) | ZA200104234B (de) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042926A1 (en) * | 1998-10-28 | 2002-04-11 | Matzuk Martin M. | Ovary-specific genes and proteins |
MXPA01005275A (es) * | 1998-11-27 | 2003-06-06 | Darwin Discovery Ltd | Composiciones y metodos para aumentar la mineralizacion de huesos. |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
AU3511100A (en) * | 1999-03-12 | 2000-10-04 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acids and polypeptides |
US20030138902A1 (en) * | 1999-08-31 | 2003-07-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001092308A2 (en) * | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
EP1857551A3 (de) * | 2000-06-01 | 2007-11-28 | Amgen Inc. | Zystinknoten-Polypeptide: 2-verhüllte Moleküle und ihre Verwendungen |
US20040132021A1 (en) * | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
AU2002230390A1 (en) * | 2000-10-05 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
US7056679B2 (en) * | 2001-10-24 | 2006-06-06 | Antyra, Inc. | Target specific screening and its use for identifying target binders |
US7202102B2 (en) * | 2001-11-27 | 2007-04-10 | Jds Uniphase Corporation | Doped absorption for enhanced responsivity for high speed photodiodes |
EP2277522B1 (de) * | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen |
US7799523B2 (en) * | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
PL378566A1 (pl) * | 2003-03-14 | 2006-05-02 | Celltech R & D, Inc. | Ligandy dla białek wiążących TGF-beta i ich zastosowania |
US20040197828A1 (en) * | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
JP3848288B2 (ja) * | 2003-04-25 | 2006-11-22 | キヤノン株式会社 | 放射線画像撮影装置 |
WO2004108160A1 (ja) * | 2003-06-05 | 2004-12-16 | Nippon Shinyaku Co., Ltd. | 骨形成促進増強剤及びそのスクリーニング方法 |
CN1835974A (zh) * | 2003-06-16 | 2006-09-20 | 细胞技术研究与发展公司 | 对硬化素特异的抗体和用于增加骨矿化的方法 |
US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
AU2003300239A1 (en) * | 2003-12-29 | 2005-07-21 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
US8415302B2 (en) | 2004-01-28 | 2013-04-09 | The Regents Of The University Of California | Surgical applications for BMP binding protein |
US8193312B2 (en) | 2004-01-28 | 2012-06-05 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
WO2005072403A2 (en) | 2004-01-28 | 2005-08-11 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
JP2008540328A (ja) * | 2004-11-29 | 2008-11-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脱灰骨基質(demineralizedbonematrix)の活性化抽出 |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2006135734A2 (en) * | 2005-06-10 | 2006-12-21 | The Regents Of The University Of California | Compositions and methods for altering bone density and bone patterning |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
KR101557375B1 (ko) * | 2005-11-23 | 2015-10-08 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
EP2423226A3 (de) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Diagnose und Therapie auf Basis von Antikörpern |
US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
WO2009131553A2 (en) | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
US20080200425A1 (en) * | 2007-02-16 | 2008-08-21 | Kurtz Seymour J | Methods and compositions for regulating bone mineral density |
US7744874B2 (en) * | 2007-03-20 | 2010-06-29 | Eli Lilly And Company | Anti-sclerostin antibodies |
WO2008157367A1 (en) * | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
US20110097318A1 (en) * | 2007-08-31 | 2011-04-28 | Amgen Inc. | Solid-State Protein Formulation |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
WO2009079471A1 (en) * | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
EP2274620A2 (de) * | 2008-04-02 | 2011-01-19 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Pcpe-(procollagen c-proteinase enhancer-)biomarker für knochenbildung |
US8518656B2 (en) | 2008-04-02 | 2013-08-27 | Ramot Tel-Aviv University Ltd. | Procollagen C-proteinase enhancer (PCPE) biomarker for bone formation |
WO2010002835A2 (en) * | 2008-07-03 | 2010-01-07 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2011005298A2 (en) | 2009-06-23 | 2011-01-13 | The Regents Of The University Of California | Enhancement of bmp retention |
WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
US20130138221A1 (en) | 2010-04-16 | 2013-05-30 | Novartis Ag | Methods and compositions for improving implant osseointegration |
ME02819B (de) | 2010-05-14 | 2018-01-20 | Amgen Inc | Hochkonzentrierte antikörperformulierungen |
US9061097B2 (en) | 2010-06-07 | 2015-06-23 | Amgen Inc. | Drug delivery device |
WO2013032527A1 (en) | 2011-09-02 | 2013-03-07 | The Regents Of The University Of California | Llp2a-bisphosphonate conjugates for osteoporosis treatment |
KR20180129991A (ko) | 2010-11-05 | 2018-12-05 | 노파르티스 아게 | Il-17 길항제를 사용한 류마티스성 관절염의 치료 방법 |
EA201391248A1 (ru) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
PL2699261T3 (pl) | 2011-04-19 | 2018-12-31 | Amgen Inc. | Metoda leczenia osteoporozy |
CA2833748C (en) | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
ES2729993T3 (es) | 2011-10-14 | 2019-11-07 | Amgen Inc | Inyector y procedimiento de ensamblaje |
MX354270B (es) | 2011-12-28 | 2018-02-21 | Amgen Inc | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . |
US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP2922590B1 (de) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Arzneimittelabgabevorrichtung |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
EP3593839A1 (de) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Arzneimittelkassette |
DK3312195T3 (da) * | 2013-03-20 | 2020-01-06 | Genzyme Corp | Fremgangsmåder til behandling af osteogenesis imperfecta |
LT2976117T (lt) | 2013-03-22 | 2021-02-25 | Amgen Inc. | Purkštuvas ir surinkimo būdas |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
AU2014340171B2 (en) | 2013-10-24 | 2019-05-30 | Amgen Inc. | Injector and method of assembly |
WO2015061389A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
EP3233163B1 (de) | 2014-12-19 | 2021-10-13 | Amgen Inc. | Medikamentenabgabevorrichtung mit näherungssensor |
CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (de) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP3721922B1 (de) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (de) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Wirkungstestvorrichtungen und verfahren für wirkstofffreisetzungsvorrichtungen |
EP3478342A1 (de) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen |
MA45921A (fr) | 2016-08-08 | 2019-06-19 | Amgen Inc | Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine. |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
EP3554256B1 (de) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Zusammensetzungen und verfahren zur modulation von vitamin d und knochenmineraliengehalt bei einem haustier |
DK3478719T3 (da) | 2016-12-21 | 2021-03-01 | Mereo Biopharma 3 Ltd | Anvendelse af anti-sclerostin-antistoffer i behandlingen af osteogenesis imperfecta |
WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
EP3582829A1 (de) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Einführmechanismus für eine arzneimittelabgabevorrichtung |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
IL303449B1 (en) | 2017-03-09 | 2024-04-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
CN114588404A (zh) | 2017-03-28 | 2022-06-07 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
EP3658203B1 (de) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (de) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
JP7247174B2 (ja) | 2017-11-10 | 2023-03-28 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプランジャ |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
AU2018368340B2 (en) | 2017-11-16 | 2024-03-07 | Amgen Inc. | Door latch mechanism for drug delivery device |
KR20200138254A (ko) | 2018-03-30 | 2020-12-09 | 암젠 인크 | C-말단 항체 변이체 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
EP3833327A1 (de) | 2018-08-10 | 2021-06-16 | Amgen Inc. | Verfahren zur herstellung einer pharmazeutischen antikörperformulierung |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
US20210338936A1 (en) | 2018-10-05 | 2021-11-04 | Amgen Inc. | Drug delivery device having dose indicator |
CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
EP3866890A1 (de) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Medikamentenabgabevorrichtung mit dämpfungsmechanismus |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
EP3873567A1 (de) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Arzneimittelabgabevorrichtungen mit teilweisem nadelrückzug |
WO2020091981A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
JP2022544495A (ja) | 2019-08-12 | 2022-10-19 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体製剤 |
US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022120080A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Massachusetts | Development of novel gene therapeutics for fibrodysplasia ossificans progressiva |
CN113354724A (zh) * | 2021-04-28 | 2021-09-07 | 蒋青 | 骨硬化蛋白及其在制备治疗或预防阿尔兹海默症的相关产品上应用 |
CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US649445A (en) * | 1899-08-31 | 1900-05-15 | James Alpheus Green | Steam-injector for fire-boxes of steam-boilers. |
US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4378110A (en) * | 1978-04-17 | 1983-03-29 | Greene Ronald W | Continuous paper sorting machine |
US4359535A (en) | 1979-10-01 | 1982-11-16 | George Pieczenik | Autonomously replicating DNA containing inserted DNA sequences |
US4528266A (en) | 1979-10-01 | 1985-07-09 | George Pieczenik | Method of inserting unique DNA sequences into DNA vectors |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4427115A (en) * | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (de) * | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
SG64329A1 (en) | 1984-11-16 | 1999-04-27 | American Cyanamid Co | Antitumor antibiotics (LL-E33288 complex) |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
ATE132266T1 (de) | 1987-05-01 | 1996-01-15 | Stratagene Inc | Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
DE3889063T2 (de) | 1987-10-30 | 1994-12-01 | American Cyanamid Co | Dischwefel-Analoge von LL-E33288 Antitumor-Verbindungen. |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
EP0329184A3 (de) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimere und antimere Konjugation |
US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
EP0454781B1 (de) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
GB8903022D0 (en) | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
GB8914543D0 (en) | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
EP1001032A3 (de) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5359051A (en) | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
ATE149841T1 (de) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
US5177197A (en) * | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
CA2085127C (en) | 1990-06-15 | 2002-12-10 | Barbara Cordell | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (ja) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
EP0554376A4 (en) | 1990-10-22 | 1994-08-24 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0575485A1 (de) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Verfahren zur entwicklung bindender miniproteine |
US6949505B1 (en) * | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0644946A4 (de) | 1992-06-10 | 1997-03-12 | Us Health | Gegen die inaktivierung durch menschliches serum resistente vektorpartikel. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
IL108719A0 (en) | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
NZ267838A (en) * | 1993-06-07 | 1997-12-19 | Genentech Inc | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains |
WO1995002566A1 (en) | 1993-07-16 | 1995-01-26 | Ontogen Corporation | Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
CA2168886A1 (en) | 1993-08-03 | 1995-02-09 | Michael Raymond Pavia | A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
WO1995016209A1 (en) | 1993-12-09 | 1995-06-15 | Ciba-Geigy Ag | Process for the production of combinatorial compound libraries |
JPH09506913A (ja) | 1993-12-15 | 1997-07-08 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
WO1995016918A1 (en) | 1993-12-15 | 1995-06-22 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
CA2183428A1 (en) | 1994-03-11 | 1995-09-14 | John J. Baldwin | Sulfonamide derivatives and their use |
CA2187902A1 (en) | 1994-04-29 | 1995-11-09 | Peter Ten Dijke | Morphogenic protein-specific cell surface receptors and uses therefor |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
ATE403001T1 (de) * | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
IL132443A0 (en) * | 1997-04-29 | 2001-03-19 | Regeneron Pharma | Human cerberus protein |
ATE386802T1 (de) * | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
CA2297109A1 (en) * | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
US6815201B2 (en) * | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6544485B1 (en) * | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
MXPA01005275A (es) | 1998-11-27 | 2003-06-06 | Darwin Discovery Ltd | Composiciones y metodos para aumentar la mineralizacion de huesos. |
EP1151002A4 (de) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | Antikörper spezifisch für kdr und ihre verwendungen |
ES2332916T3 (es) | 1999-06-09 | 2010-02-15 | Genentech Inc | Composiciones y metodo para el tratamiento de tumores. |
JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
AR029814A1 (es) | 2000-03-02 | 2003-07-16 | Amgen Inc | Moleculas emparentadas con chordin 2 y usos de las mismas |
WO2001092308A2 (en) * | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
US20040132021A1 (en) | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
AU2002216610A1 (en) | 2000-09-01 | 2002-04-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1324776B2 (de) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Niederviskose konzentrierte proteinformulierungen |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
BRPI0214680B1 (pt) | 2001-12-06 | 2018-09-18 | Biocontrol Systems Inc | instrumento para uso em monitorar um produto, um ingrediente, um ambiente ou processo, instrumento para detectar emissão de luz de uma amostra e método de monitorar uma amostra de um produto, um ingrediente, um processo ou ambiente |
US20030186915A1 (en) * | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
EP2277522B1 (de) | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen |
US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
CA2504493C (en) | 2002-11-01 | 2015-12-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) * | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
PL378566A1 (pl) | 2003-03-14 | 2006-05-02 | Celltech R & D, Inc. | Ligandy dla białek wiążących TGF-beta i ich zastosowania |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
CN1835974A (zh) * | 2003-06-16 | 2006-09-20 | 细胞技术研究与发展公司 | 对硬化素特异的抗体和用于增加骨矿化的方法 |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
US7709611B2 (en) | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8541177B2 (en) | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
EP2423226A3 (de) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Diagnose und Therapie auf Basis von Antikörpern |
WO2009131553A2 (en) | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
AU2008209713B2 (en) | 2007-02-02 | 2012-01-19 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
US7744874B2 (en) | 2007-03-20 | 2010-06-29 | Eli Lilly And Company | Anti-sclerostin antibodies |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
EP2567709B1 (de) | 2007-11-02 | 2017-12-27 | Novartis AG | Moleküle und Verfahren zum Modulieren eines Lipoproteinrezeptor-assoziierten Proteins 6 (LRP6) mit geringer Dichte |
WO2009079471A1 (en) | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
RU2010153580A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двумя вариабельными доменами и их применение |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
CA2815181C (en) | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
-
1999
- 1999-11-24 MX MXPA01005275A patent/MXPA01005275A/es active IP Right Grant
- 1999-11-24 ES ES99963986.7T patent/ES2272093T5/es not_active Expired - Lifetime
- 1999-11-24 EP EP06011535A patent/EP1721979B1/de not_active Revoked
- 1999-11-24 PT PT06011535T patent/PT1721979E/pt unknown
- 1999-11-24 DK DK10008049.8T patent/DK2261335T3/en active
- 1999-11-24 MX MX2013001685A patent/MX343200B/es unknown
- 1999-11-24 DE DE69933044.0T patent/DE69933044T3/de not_active Expired - Lifetime
- 1999-11-24 NZ NZ512122A patent/NZ512122A/en not_active IP Right Cessation
- 1999-11-24 IL IL14326699A patent/IL143266A0/xx active IP Right Grant
- 1999-11-24 ES ES06011535T patent/ES2350454T3/es not_active Expired - Lifetime
- 1999-11-24 DK DK06011535.9T patent/DK1721979T3/da active
- 1999-11-24 EP EP99963986.7A patent/EP1133558B2/de not_active Expired - Lifetime
- 1999-11-24 JP JP2000585404A patent/JP4813660B2/ja not_active Expired - Lifetime
- 1999-11-24 EP EP10008049.8A patent/EP2261335B1/de not_active Expired - Lifetime
- 1999-11-24 BR BRPI9915679A patent/BRPI9915679B8/pt not_active IP Right Cessation
- 1999-11-24 WO PCT/US1999/027990 patent/WO2000032773A1/en active Application Filing
- 1999-11-24 ES ES10008049.8T patent/ES2639020T3/es not_active Expired - Lifetime
- 1999-11-24 DK DK99963986.7T patent/DK1133558T4/en active
- 1999-11-24 NZ NZ552959A patent/NZ552959A/en not_active IP Right Cessation
- 1999-11-24 CA CA2352532A patent/CA2352532C/en not_active Expired - Lifetime
- 1999-11-24 AT AT99963986T patent/ATE338120T2/de active
- 1999-11-24 CN CN2008100992340A patent/CN101469329B/zh not_active Expired - Lifetime
- 1999-11-24 PT PT100080498T patent/PT2261335T/pt unknown
- 1999-11-24 NZ NZ568033A patent/NZ568033A/en not_active IP Right Cessation
- 1999-11-24 PT PT99963986T patent/PT1133558E/pt unknown
- 1999-11-24 US US09/449,218 patent/US6395511B1/en not_active Expired - Lifetime
- 1999-11-24 DE DE69942782T patent/DE69942782D1/de not_active Expired - Lifetime
- 1999-11-24 AT AT06011535T patent/ATE481487T1/de active
- 1999-11-24 CN CN99815505.5A patent/CN1333828B/zh not_active Expired - Lifetime
-
2000
- 2000-09-21 US US09/668,037 patent/US6495736B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,529 patent/US6489445B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,021 patent/US6803453B1/en not_active Expired - Lifetime
-
2001
- 2001-05-21 IL IL143266A patent/IL143266A/en not_active IP Right Cessation
- 2001-05-23 ZA ZA200104234A patent/ZA200104234B/en unknown
-
2002
- 2002-03-07 US US10/095,248 patent/US7572899B2/en not_active Expired - Fee Related
- 2002-07-26 HK HK02105515.3A patent/HK1044171B/zh not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/384,893 patent/US7192583B2/en not_active Expired - Lifetime
-
2004
- 2004-02-27 US US10/788,606 patent/US7758858B2/en not_active Expired - Fee Related
-
2006
- 2006-11-09 CY CY20061101623T patent/CY1106260T1/el unknown
-
2007
- 2007-10-31 US US11/931,768 patent/US7994299B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,853 patent/US20110150866A1/en not_active Abandoned
- 2007-10-31 US US11/931,812 patent/US7977312B2/en not_active Expired - Fee Related
-
2009
- 2009-12-31 HK HK09112388.6A patent/HK1135726A1/xx not_active IP Right Cessation
-
2010
- 2010-12-10 CY CY20101101148T patent/CY1110982T1/el unknown
- 2010-12-30 IL IL210392A patent/IL210392A/en not_active IP Right Cessation
-
2011
- 2011-06-30 JP JP2011145326A patent/JP5691036B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-04 US US13/644,728 patent/US8986685B2/en not_active Expired - Fee Related
-
2015
- 2015-02-19 US US14/626,274 patent/US9791462B2/en not_active Expired - Fee Related
-
2017
- 2017-08-30 CY CY20171100914T patent/CY1119263T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69933044D1 (de) | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung | |
DE60120114D1 (de) | Verfahren zur Verbesserung der Knochenmineralisierung | |
DE69725169D1 (de) | Zusammensetzungen und verfahren zur anregung des wachstums von neuriten | |
MXPA03011236A (es) | Vehiculos de liberacion de fosfato de calcio para proteinas osteoinductivas. | |
DE60004496D1 (de) | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff | |
DE60237905D1 (de) | Set zur Entnahme von Knochenmark | |
ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
ATE508755T1 (de) | Verfahren zur inaktivierung von biologischen schadstoffen mithilfe von photosensibilisatoren | |
DE60227095D1 (de) | Zusammensetzungen und verfahren zur behandlung von abgebundenem gips | |
DE69835810D1 (de) | Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur | |
ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
ATE233049T1 (de) | Zusammensetzung und verfahren zur kontrolle von schädlichen bio-organismen | |
DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
DE60126156D1 (de) | Verfahren und vorrichtung zur herstellung von knochenzement | |
DE602004005477D1 (de) | Injizierbare feste calciumphosphat-stäbe zur abgabe von osteogenen proteinen | |
DE50205653D1 (de) | Verfahren zur festlegung von zeitpunkt und umfang von wartungsvorgängen | |
ATE486931T1 (de) | Hybridpolymerase-verfahren und -zusammensetzungen | |
DE69834578D1 (de) | Verfahren zur behandlung von zementaufschlämmungen | |
DE602004032345D1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
EP1399023A4 (de) | Zusammensetzungen und verfahren für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren | |
ATE212855T1 (de) | Verfahren und zusammensetzungen zur behandlung von rheumatoider arthritis | |
DE69919568D1 (de) | Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen | |
DE60210645D1 (de) | Zusammensetzung und verfahren zur behandlung von oberflächen | |
DE69821826D1 (de) | Verfahren und Zusammensetzung zur Zementierung von Bohrlöcher | |
ATE419348T1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: UCB PHARMA S.A., BRUESSEL/BRUXELLES, BE |